Katherine A. Eade
Director at Harvard Bioscience Inc (HBIO)
Katherine A. Eade has filed 10 insider reports with the SEC since May 2021, as director at Harvard Bioscience Inc (HBIO) and director at Vaxxinity, Inc. (VAXX). The latest filing, on June 12, 2026, reports grant or award at Harvard Bioscience Inc (HBIO).
- Filings
- 10
- Companies
- 2
- Bought on market
- None
- Sold on market
- None
Companies where Katherine A. Eade is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Director | 58,669 | $8.66 | Jun 12, 2026 | ||||
| Directorsince February 2023 | Jun 26, 2023 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Jun 9, 2026HBIODirector Eade Katherine A. was granted 16,556 shares, increasing direct ownership by 39% to 58,669 unitsForm 4Grant or award
- Jul 16, 2025HBIODirector Eade Katherine A. was granted 110,000 shares, increasing direct ownership by 35% to 421,126 unitsForm 4Grant or award
- May 21, 2024HBIOEade Katherine A. was granted 45,872 shares, increasing direct ownership by 17% to 311,126 unitsForm 4Grant or award
- Jun 20, 2023VAXXSEC Form 4 filed by Eade Katherine A.Form 4Grant or award
- May 22, 2023HBIOSEC Form 4 filed by Eade Katherine A.Form 4Grant or award
- Feb 1, 2023VAXXKatherine A. Eade became an insiderForm 3New insider
- May 24, 2022HBIOSEC Form 4: Eade Katherine A. was granted 38,259 shares, increasing direct ownership by 19% to 239,700 unitsForm 4Grant or award
- Jan 1, 2022HBIOSEC Form 4: Eade Katherine A. was granted 2,525 shares, increasing direct ownership by 1% to 201,441 unitsForm 4Grant or award
- Dec 28, 2021HBIOSEC Form 4: Eade Katherine A. was granted 1,401 shares, increasing direct ownership by 0.71% to 198,916 unitsForm 4Grant or award
- May 25, 2021HBIOSEC Form 4: Eade Katherine A. was granted 14,400 units of Common Stock, increasing direct ownership by 8% to 197,515 unitsForm 4Grant or award
Compare Katherine A. Eade with
- Katherine A. Eade vs William Snider1 shared
- Katherine A. Eade vs Stephen J Denelsky1 shared
- Katherine A. Eade vs Robert E. Gagnon1 shared
- Katherine A. Eade vs Seth Benjamin Benson1 shared
- Katherine A. Eade vs Mark T Frost1 shared
- Katherine A. Eade vs John D Duke1 shared
Other insiders at the same companies
- William SniderHBIO
- Stephen J DenelskyHBIO
- Robert E. GagnonHBIO
- Seth Benjamin BensonHBIO
- Mark T FrostHBIO
- John D DukeHBIO
- James W GreenHBIO
- Jennifer CoteHBIO
Questions about Katherine A. Eade
- What is Katherine A. Eade's role at Harvard Bioscience Inc?
- Katherine A. Eade reports to the SEC as director at Harvard Bioscience Inc (HBIO), according to the latest filing on June 12, 2026. Katherine A. Eade has also filed as director at Vaxxinity, Inc. (VAXX).
- How many shares does Katherine A. Eade own?
- After the latest filing that states it, Katherine A. Eade directly owned 58,669 shares of Harvard Bioscience Inc (HBIO). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Katherine A. Eade bought or sold stock recently?
- No open-market purchases or sales by Katherine A. Eade are on file. The filings report grant or award.
- How do I get alerts when Katherine A. Eade files?
- Follow Katherine A. Eade on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Katherine A. Eade (SEC CIK 0001721318). Totals count each trade once, skipping amendments whose original is on file, from May 27, 2021 on. View on SEC EDGAR · Get this as JSON